Table 2 Logistic regression analysis of predictors for clinical improvement in new-onset MG patients before COVID-19 outbreak

Baseline MG-ADL

1.720 (1.339, 2.211)

 < 0.001*

1.687 (1.282, 2.220)

 < 0.001*

Age at the onset

1.004 (0.986, 1.022)

0.697

0.987 (0.976, 1.008)

0.216

Vaccine

1.561 (0.666, 3.655)

0.305

Pyridostigmine

2.204 (0.589, 8.241)

0.240

1.422 (0.275, 7.365)

0.675

Immunosuppressant

1.616 (0.572, 4.567)

0.365

Prednisolone

2.442 (1.165, 5.117)

0.018*

1.667 (0.679, 4.091)

0.265

RNS-positive

1.925, (0.928, 3.396)

0.079

1.233 (0.506, 3.000)

0.645

Abnormal thymus

0.904 (0.436, 1.873)

0.786

Antibody status

1.171 (0.592, 2.316)

0.650

Smoking

1.561 (0.594, 4.105)

0.366

Season of onset

1.215 (0.840, 1.756)

0.301

1.187 (0.788, 1.786)

0.412

MGFA ≥ III

4.796 (1.388, 16.568)

0.013*

1.382 (0.256, 7.465)

0.707

Generalized MG

3.189 (1.515, 6.715)

0.002*

0.917 (0.312, 2.697)

0.875

Affect bulbar or respiratory muscles

4.037 (1.580, 10.312)

0.004*

1.558 (0.341, 6.160)

0.616

Infection rate

2.453 (0.525, 11.459)

0.254

MG duration

1.000 (0.976, 1.024)

0.972

Gender, male

1.179 (0.571, 2.432)

0.657